CiDA 2018  | NOVEMBER 1-2, 2018

SoDA 2018 | OCTOBER 31, 2018

The Marriott Marquis, Washington, D.C.


2018 Scientific Program



WedneSDAY, OCTOBER 31, 2018

VIEW SoDA Program



6:30 a.m.
Registration, Continental Breakfast and Industry Session
7:30 a.m.Welcome and Introduction: The Future of Renal Replacement



Session #1: Incidence, Prevalence and Trends in Renal Replacement

7:40 a.m.Report from India
7:47 a.m.Report from USA
7:54 a.m.Report from Scandinavia
8:01 a.m.

Panel Discussion




Debate #1: Renal Replacement: To Live or Let Die?

8:15 a.m.Our Society Cannot Afford Renal Replacement for Everyone
8:20 a.m.Is Comprehensive ESRD Care the Responsibility of a Society?

8:25 a.m.

Panel Discussion: Patient's Responsibility 



Session #2: Can We Afford to Improve Dialysis Access Care?

8:35 a.m.How the FDA Approaches Review of Disruptive Technology
8:42 a.m.The CMS Approach to Dialysis Access Maintenance: Shaping the Future of Care
8:49 a.m.The Realities of Running a Clinically Successful Out-of-Hospital Practice
9:06 a.m.How Doctors Should be Paid: Pay-for-Procedure? Pay-for-Performance?
9:13 a.m.Panel Discussion: Time to Get Out of the ESRD Business? 



Debate #2: Stent-grafts and DCB’s: Affordable?

9:20 a.m.New, Effective and Unaffordable
9:25 a.m.New, Effective and Will Reduce the Total Cost of Care 

9:30 a.m.

Panel Discussion: Can Better but Costlier Care be Provided in a Fee-for-Service Reimbursement System? 



Case #1: Follow Up from Cases at 2017 CiDA (As Promised!)

9:40 a.m.

Panel Discussion and Audience Participation 
10:00 a.m.Refreshment Break With the Exhibitors 



Session #3: AV Access Maintenance Clinical Trial Updates

10:30 a.m.The LUTONIX AV IDE Trial 
10:37 a.m.The DCB Registry 
10:44 a.m.IN.PACT Trial
10:51 a.m.AVeVA Trial 12-month and AVeNEW Trial First Look 
10:58 a.m.Stem Cells for Preventing Vascular Injury in AVF: From Bench to Bedside 
11:05 a.m.Phase 3 Study of Vonapanitase in Radiocephalic AVF’s: 600 Patients Later 
11:12 a.m.Panel Discussion: Which Innovations Will Matter the Most? 



Case #2: AVF Stenosis. Now What?

11:22 a.m.Panel Discussion and Audience Participation 
12:00 p.m.Lunch and Industry Sessions 



Session #4: Creating Useful, Mature and Useable AV Fistulae

1:30 p.m.Timing of Pre-emptive AVF and the Kidney Failure Risk Equation (KFRE):  What You Can Tell Your Patients Today 
1:37 p.m.The DAC AVF Immaturity Study. What is “Immaturity” and What Are Its Causes? 
1:44 p.m.Five Things Surgeons Should NEVER Do When Creating an AVF 
1:51 p.m.Five Things Surgeons Should ALWAYS Do When Creating an AVF 
1:58 p.m.Panel Discussion: Get it Right the First Time 
 Case #3: AVF Creation Based Upon the Kidney Failure Risk Equation (KFRE) 
2:06 p.m.

Panel Discussion and Audience Participation


Session #5: Lumen versus Lesion: What Are We Treating?

2:26 p.m.Histology of AVF Stenosis and Implications for Treatment 
2:33 p.m.Late Breaking Lecture 
 Debate #3: Tissue Characteristic of an AVF Stenosis
2:40 p.m.The Issue is Tissue and the Solution to Creating and Maintaining Long Lasting AV Access is On the Cellular Level 
2:45 p.m.Cellular? In Our Lifetime? Stent Grafts and DCB’s Are Here Now 
2:50 p.m.Panel Discussion:  Today, Tomorrow and Beyond  
3:00 p.m.Refreshment Break with Exhibitors



Session #6: Renal Transplantation and Peritoneal Dialysis

3:30 p.m.Current State of Cadaveric Donor Transplantation 
3:37 p.m.
Living Related Transplantation: An Update 
3:44 p.m.Peritoneal Dialysis: An Update 
3:51 p.m.Failure Modes of Peritoneal Dialysis 
3:58 p.m.Panel Discussion: PD or HD…What Would You Choose for Yourself?
 Case #4: Catheter Capers
4:08 p.m.

Panel Discussion and Audience Participation

4:30 p.m.It’s Access Academic
 Team 1:
 Team 2:
 Team 3:
5:30 p.m.ADJOURN DAY #1 


Friday, November 2, 2018

 "The Computer Will See You Now” - The Future of Medicine?
 Session #7: Decisions that Guide Optimal Outcomes
8:00 a.m.INTRO: 300 Access Options - Too Much for the Human Brain 
8:10 a.m.

C-communication-IQ in a Complex System

8:17 a.m.The Computer Will See You Now: Meet Your New Boss – Mr. Algorithm 
 Debate #4: How to Achieve the Best Outcomes When Creating Dialysis Access
8:24 a.m.An Experienced Physician is a Far Better Decision Maker Than Any Algorithm 
8:29 a.m.Best Decisions are Based Upon Data and Analytics That Can Be Used to Create Algorithms for Optimal Care 
8:34 a.m.Panel Discussion: Are We Smarter Than the Computer or Too Dumb to Realize We Aren’t?
8:44 a.m.
You Arrived Alive to DC: What Healthcare Can Learn from Aviation 
8:51 a.m.Panel Discussion: Are YOU Safe at Work? Ready for the “Black Box” in the OR? 
 Session #8: Thou Shall Not Steal
9:01 a.m.Algorithms for Distal Hypo-perfusion (DASS) 



Case #5: Steal

9:08 a.m.Panel Discussion



Session #9: AV Access Creation Clinical Trial Updates

9:30 a.m.HUMANITY Trial Update 
9:37 a.m.SAVE-US Pivotal Trial and European Experience Updates 
9:44 a.m.EndoAVF: Update from European Experience and US Trial Data 
9:52 a.m.tRAD AVF: ELLIPSYS Trial Results Update
10:00 a.m.

Refreshment Break with the Exhibitors




Case #6: EndoAVF Creation LIVE Cases

10:30 a.m.

1st Case:  10:30-10:50 (20 min)

2nd Case:  10:50-11:10 (20 min)


Session #10: Thoracic Central Vein Obstruction (TCVO): “Deep Dive” into the Dark Blue Pool

11:10 a.m.Finally, the SIR TCVO Reporting Standards are Here. What You Should Know 
11:17 a.m.Bare Metal Stents for TCVO: RIP…or Not? 
11:24 a.m.Drug Coated Balloons for TCVO: Any Signal That This Works? 
11:31 a.m.The Role for Stent-Grafts for TCVO: What We’ve Learned So Far
11:38 a.m.

Surgery for Symptomatic TCVO: Flow Reduction, Graft Catheters and more

11:46 a.m.

Panel Discussion: TCVO – An Unmet Need

12:00 p.m.

Lunch and Industry Sessions



1:30 p.m.Concurrent Clinic Session 
 Clinic A
 Peritoneal Dialysis
 Clinic B
 Thoracic Central Vein Obstruction
 Clinic C
 The Clotted AV Access
2:30 p.m.

Refreshment Break with the Exhibitors

3:00 p.m.

Keynote Lectures: Did You Mean What You Said and Said What You Meant?

Communication IQ. Do You Have It and Can It Be Learned?

3:15 p.m.

Keynote Lectures: Did You Mean What You Said and Said What You Meant?

Avoiding Disaster: What is Aviation Doing So Right? What Can It Do Better?

 CASE #7: Cases Now for Follow Up Next Year
3:30 p.m.Panel Discussion and Audience Participation 
3:55 p.m. _____________Concluding Remarks from CiDA 2018